Cellworks > Resources > Bibliography



V2a Kit - From Vasculogenesis to Angiogenesis

BPC 157 and blood vessels.

Seiwerth, Sven, et al.


Current Pharmaceutical Design 20.7 (2014): 1121-1125.

Effects of BPC 157 on blood vessels after various types of damage and the different aspects of vascular response. BPC was found to be a potent angiomodulatory agent acting through different vasoactive pathways and systems. The V2a Kit: Vasculogenesis to Angiogenesis was used to investigate the angiogenic effect of BPC 157 both with and without VEGF and Suramin.

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer.

Stengel, C., et al.


British Journal Of Cancer 111.2 (2014): 300-308.

STZ2484 is a novel non-steroidal compound with potent anti-proliferative activity. V2a Kit: Vasculogenesis to Angiogenesis was used to investigate the effect of STX2484 on in vitro vessel formation.

Shed syndecan-2 inhibits angiogenesis.

De Rossi, Giulia, et al.


Journal Of Cell Science 127.21 (2014): 4788-4799.

Results demonstrate that shed syndecan-2 regulates angiogenesis by inhibiting endothelial cell migration in human and rat models; and reduces tumour growth. The V2a Kit: Vasculogenesis to Angiogenesis was used to investigate the effect of S2ED in vitro.

Soluble VEGF receptor-1 improves therapeutic efficacy of suicide gene therapy in an angiogenesis independent manner.

Samaranayake, Haritha D., et al.


Human Gene Therapy Ja (2014).

Demonstration of the feasibility of combining adenovirus-mediated soluble vascular endothelial growth factor-1 anti-angiogenic gene therapy with AdHSv-tk/GVC suicide gene therapy to treat experimental malignant gliomas. The functionality of Ads VEGFR-1 was tested using the V2a Kit: Vasculogenesis to Angiogenesis.

AngioSys - Angiogenesis Image Analysis Software

Comparison of two in vitro angiogenesis assays for evaluating the effects of netrin-1 on tube formation.

Guo, Hui, et al.


Acta Biochimica Et Biophysica Sinica(2014):

Co-cultured HUVEC

Call for papers

Cellworks would like to hear from all customers who have published using Cellworks products.

Please contact Caltag Medsystems office@caltagmedsystems.co.uk or telephone +44 (0)1280 827460 with the following details:

  • Researcher Name
  • Researcher Email
  • Article and Journal Title
  • Cellworks Product Used

Webmaster: AnnWebCom  |  Cellworks is a Caltag Medsystems company.  |  © 2012-2020 Caltag Medsystems Ltd. - all rights reserved  |  Privacy & Cookies